

### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of claims:

1-30. (canceled)

31. (currently amended) A method of treating cancer comprising administering to an individual ~~in need thereof~~ having a cancer an effective amount of a composition comprising a *Quillaja saponaria* saponin or a chemically modified form thereof, wherein said effective amount stimulates innate immunity, thereby treating said cancer, and wherein said composition does not contain a vaccine antigen.

32. (canceled)

33. (currently amended) The method as claimed in claim 31, wherein said composition comprises a chemically modified form of said *Quillaja saponaria* saponin ~~is chemically modified~~.

34. (currently amended) The method as claimed in claim 31, wherein said *Quillaja saponaria* saponin or chemically modified form thereof is substantially pure.

35. (previously presented) The method as claimed in claim 34, wherein said substantially pure *Quillaja saponaria* saponin is QS-7, QS-17, QS-18, or QS-21.

36. (previously presented) The method as claimed in claim 35, wherein said substantially pure *Quillaja saponaria* saponin is QS-21.

37. (previously presented) The method as claimed in claim 31, wherein said individual is a mammal.

38. (previously presented) The method as claimed in claim 31, wherein said individual is a human.

39. (canceled)

40. (currently amended) The method as claimed in claim 31, wherein said effective amount of a said composition ~~comprising a~~ *Quillaja saponaria* saponin is an amount sufficient to ~~enhance~~ enhance a natural killer cell response.

41-43. (canceled)

44. (previously presented) The method as claimed in claim 40, wherein said enhanced natural killer cell response is evaluated by an *in vitro* assay comprising:

(a) contacting natural killer cell-sensitive target cells with effector cells, wherein said effector cells are from said individual that has been administered said composition; and

(b) determining the level of lysis of said natural killer cell-sensitive target cells; wherein increased lysis of natural killer cell-sensitive target cells contacted with effector cells from said individual that has been administered said composition as compared to natural killer cell-sensitive target cells contacted with effector cells from an individual that has not been administered said composition indicates an enhanced natural killer cell response.

45. (previously presented) The method as claimed in claim 31, 33, 34, 35, 36, 37, 38 or 40, wherein said composition does not contain an oligonucleotide comprising at least one unmethylated CpG dinucleotide.

46. (previously presented) The method as claimed in claim 31, 33, 34, 35, 36, 37, 38 or 40, wherein said composition further comprises an oligonucleotide comprising at least one unmethylated CpG dinucleotide.

47. (new) The method as claimed in claim 34, wherein said composition comprises a substantially pure *Quillaja saponaria* saponin selected from the group consisting of QS-7, QS-17, QS-18, and QS-21.

48. (new) The method as claimed in claim 47, wherein said substantially pure *Quillaja saponaria* saponin is QS-21.

49. (new) The method as claimed in claim 47 or 48, wherein said composition does not contain an oligonucleotide comprising at least one unmethylated CpG dinucleotide.

50. (new) The method as claimed in claim 47 or 48, wherein said composition further comprises an oligonucleotide comprising at least one unmethylated CpG dinucleotide.

51. (new) The method as claimed in claim 46, wherein said oligonucleotide is TCTCCCAGCGTGCGCCAT (SEQ ID NO: 2), TCCATGACGTTTCCTGACGTT (SEQ ID NO: 3), or TCGTCGTTTTGTGCGTTTTGTCGTT (SEQ ID NO: 4).

52. (new) The method as claimed in claim 50, wherein said oligonucleotide is TCTCCCAGCGTGCGCCAT (SEQ ID NO: 2), TCCATGACGTTTCCTGACGTT (SEQ ID NO: 3), or TCGTCGTTTTGTGCGTTTTGTCGTT (SEQ ID NO: 4).

53. (new) The method as claimed in claim 34, wherein said composition comprises a mixture of two or more substantially pure *Quillaja saponaria* saponins selected from the group consisting of QS-7, QS-17, QS-18, and QS-21.

54. (new) The method as claimed in claim 47, wherein said composition comprises a mixture of two or more substantially pure *Quillaja saponaria* saponins selected from the group consisting of QS-7, QS-17, QS-18, and QS-21.